Toxicidad por Cobre

Standardized pollen extracts (Cernilton/Graminex) have been evaluated in multiple clinical trials for benign prostatic hyperplasia (BPH) and chronic prostatitis. A Cochrane review found pollen extract modestly improves urinary symptoms compared to placebo, particularly nocturia. In China, rapeseed bee pollen-based pharmaceutical capsules are a first-line treatment for chronic non-bacterial prostatitis.

Observational studies and nested case-control analyses have found that higher blood levels of non-alpha tocopherols are inversely associated with prostate cancer risk. Delta-tocopherol combined with gamma-tocopherol has demonstrated reinforced anti-proliferative activity against androgen-dependent prostate cancer cells in vitro. Gamma-tocopherol and its metabolites are linked to reduced prostate cancer risk through COX-2 inhibition and sphingolipid pathway disruption.

Beta-sitosterol, a plant sterol found in many plants and concentrated in saw palmetto, has robust clinical evidence for improving urinary symptoms in BPH. A Cochrane review of four RCTs found significant improvements in IPSS, peak urinary flow, and post-void residual volume. It inhibits 5α-reductase and prostaglandin synthesis in prostate tissue, though it does not reduce prostate size.

Brassicasterol isolated from seahorse (Hippocampus abdominalis) demonstrated specific anti-cancer activity in androgen-dependent prostate cancer cell lines (LNCaP) in vitro, downregulating androgen receptor (AR) and PSA expression and inducing apoptosis. The mechanism involves dual inhibition of AKT and AR signaling pathways. This evidence is currently limited to in vitro cell studies; no human clinical trials exist.

Campesterol has been investigated as an inhibitor of 5α-reductase type 2, the enzyme converting testosterone to the pro-proliferative DHT, in an in vitro and molecular docking study. It is a component of saw palmetto extract and phytosterol blends studied for BPH-related prostate health. Beta-sitosterol has the strongest phytosterol evidence for prostate health; campesterol's individual contribution is less established.

Prospective studies associate high cauliflower and cruciferous vegetable intake with reduced aggressive prostate cancer risk. I3C, DIM, and sulforaphane from cauliflower inhibit androgen signaling, induce apoptosis, and trigger tumor suppressor activity in prostate cancer cells. Phase I clinical data with DIM show PSA reduction.

Modified citrus pectin has been studied in two Phase II clinical trials for prostate cancer management. In a prospective Phase II study of 60 patients with non-metastatic biochemically relapsed prostate cancer, P-MCP (4.8 g × 3/day) improved PSA doubling time in 75% of patients at 6 months. MCP's mechanism involves competitive inhibition of galectin-3, which promotes prostate cancer cell survival and metastasis.

Curcumin, the principal bioactive polyphenol in turmeric (Curcuma longa), has been studied in RCTs as part of multi-ingredient prostate cancer protocols and is among the dietary compounds with evidence in prostate carcinogenesis pathways. The Pomi-T RCT showed significant PSA growth rate reduction using a blend containing curcumin. Preclinical studies show anti-androgenic, anti-proliferative, and pro-apoptotic effects on prostate cells.

Delta-tocopherol demonstrates potent inhibitory effects on prostate cancer cells in vitro and in vivo, surpassing α-tocopherol. It suppresses androgen receptor (AR) activity and lowers PSA levels in prostate cancer cell models. In xenograft animal models, δ-T had a more potent inhibitory effect on prostate tumor formation and growth than α-tocopherol. Human clinical trial evidence isolating δ-tocopherol specifically is not yet available, though the preclinical evidence base is substantial.

DIM (3,3'-diindolylmethane) is the acid-derived dimer and bioactive product of indole-3-carbinol (I3C), acting as the first pure androgen receptor antagonist from cruciferous plants. Clinical studies of DIM supplementation before prostatectomy suggest benefit in slowing prostate cancer progression. DIM inhibits histone deacetylase activity and regulates gene expression relevant to cell cycle and proliferation in prostate cells.

EGCG, the principal catechin in green tea, is identified by the NCI's PDQ as one of the most potent modulators of molecular pathways relevant to prostate carcinogenesis. It inhibits androgen receptor signaling, suppresses PSA production, induces apoptosis, and reduces prostate tumor size in preclinical models. Early-phase clinical trials confirm accumulation in prostate tissue.

Flaxseed is rich in lignans (secoisolariciresinol diglucoside) that are converted by gut bacteria to enterolactone and enterodiol, which have anti-androgenic and anti-estrogenic properties relevant to prostate health. Whole flaxseed and flaxseed oil are commonly recommended in both Europe and the US as treatments for prostate disease, though clinical evidence is limited. The phytotherapeutic RCT systematic review includes flaxseed/linseed among examined agents for biochemically recurrent prostate cancer.

A seminal nested case-control study (Johns Hopkins, n=10,456) found high serum γT was strongly associated with reduced prostate cancer risk, and protective effects of selenium and α-tocopherol were observed only when γT was also elevated. However, a larger PLCO trial nested case-control study (n=680 cases) found γT non-significantly associated with elevated risk, illustrating inconsistency. Animal and cell-line data support anti-proliferative and pro-apoptotic actions of γT in prostate cancer cells.

Ganoderma lucidum triterpenes exhibit 5α-reductase inhibitory activity and inhibit growth, migration, and invasion of prostate cancer cell lines in vitro. A clinical trial also found a small but statistically significant reduction in prostate volume in BPH patients.

Genistein, the principal isoflavone in soy, inhibits prostate cancer cell growth, reduces PSA production, and blocks androgen receptor signaling. It has been examined in multiple RCTs for PSA modulation in prostate cancer patients and in men with elevated prostate cancer risk. Epidemiological data link high soy intake in Asian men to lower prostate cancer incidence.

Clinical studies have investigated the combination of glutamic acid, glycine, and alanine for benign prostatic hyperplasia (BPH), with one placebo-controlled trial reporting reduction in urinary symptoms in approximately half of treated patients. Mendelian randomization and metabolomic studies have identified an inverse association between serum glutamate levels and prostate cancer risk, though causality has not been firmly established.

Green tea and its catechins (particularly EGCG) have demonstrated anti-prostate cancer potential in epidemiological, preclinical, and early-phase clinical studies. Observational studies link regular green tea consumption to reduced prostate cancer risk. One study found weak evidence green tea extracts may reduce BPH symptoms. EGCG accumulates in prostate tissue after oral supplementation.

HMR has demonstrated anticancer activity in a prostate cancer animal model: dietary HMR inhibited LNCaP human prostate cancer xenograft growth in athymic male mice, reducing tumor volume and take rate and increasing apoptosis. Epidemiological evidence also links higher enterolactone levels with reduced prostate cancer risk.

HMRlignan is the only dietary lignan tested in an animal prostate cancer model, where dietary HMR significantly inhibited LNCaP human prostate cancer xenograft growth, reducing tumor volume, tumor take rate, and increasing apoptosis. Enterolactone, HMR's metabolite, induced apoptosis in human LNCaP cells via mitochondrial/caspase pathways in vitro. No human RCT exists; epidemiological evidence is inconsistent.

In a mouse xenograft model, dietary HMR inhibited the growth of LNCaP human prostate cancer cells, producing smaller tumor volumes, lower tumor take rates, and increased apoptosis compared to controls. HMR may act through aromatase inhibition and anti-androgenic mechanisms. No completed human clinical trials on HMR for prostate health have been published.

Indole-3-carbinol (I3C), derived from hydrolysis of glucobrassicin in cruciferous vegetables, inhibits prostate cancer cell growth in vitro and in vivo, induces G1 cell-cycle arrest, and modulates androgen-dependent pathways. Its active dimer DIM shows early-phase clinical evidence of slowing prostate cancer progression. Epidemiological data link cruciferous vegetable intake to decreased prostate cancer risk.

Lignans and their metabolites have attracted interest as chemopreventive agents for prostate cancer. An individual participant data meta-analysis pooling seven large studies found generally modest associations between circulating lignans and prostate cancer risk. A clinical study showed that men consuming flaxseed daily before prostate surgery had reduced tumour cell proliferation compared to controls.

Lycopene, the red carotenoid concentrated in tomatoes, has been studied for prostate cancer prevention and BPH. Multiple epidemiological studies link higher lycopene consumption with decreased prostate cancer risk. In vitro and in vivo studies show inhibition of prostate cell proliferation, induction of apoptosis, and reduced metastatic capacity. Clinical trial evidence for cancer prevention remains inconclusive.

Multiple animal studies show red maca specifically reduces prostate size in testosterone-induced BPH models, with effects exceeding finasteride in some comparisons. Traditional Andean use for prostate support in older men is also documented. No human clinical trials have been conducted.

Myristoleic acid — the free acid form of the myristoleate moiety in CMO — has been identified as the cytotoxic component in saw palmetto (Serenoa repens) that induces apoptosis and necrosis in human prostate cancer LNCaP cells (Iguchi et al., Prostate, 2001). This is in vitro evidence only; no clinical trials of CMO for prostate conditions have been published.

Nettle root (Urtica dioica) is used in traditional European medicine and has clinical trial support for BPH. A meta-analysis of 6 RCTs (1,210 patients) showed modest improvement in IPSS scores versus placebo. A double-blind RCT in 100 patients showed significant AUA score reduction (26.5 to 2.1, p<0.001) with nettle versus no change in placebo.

Nexrutine (P. amurense bark extract) demonstrated favorable effects on prostate cancer in vitro and in vivo, was evaluated in a human clinical tolerance study in prostate cancer patients (Swanson et al., 2014), and inhibits prostatic contractility relevant to BPH. A randomized placebo-controlled study examined Phellodendron Bawei tablets for BPH storage symptoms.

Beta-sitosterol, the primary phytosterol, has well-documented clinical efficacy in benign prostatic hyperplasia (BPH). Multiple RCTs including a landmark Lancet trial show significant improvements in urinary symptom scores and objective flow measures. A Cochrane systematic review covering four RCTs (n=519 men) confirms consistent improvements.

A PubMed review confirmed that urinary symptoms of benign prostatic hyperplasia (BPH) are reduced by Pycnogenol (pine bark extract) in clinical studies. This is included in the NIH LiverTox list of purported and studied uses. BPH-related urinary symptom relief is documented in the scientific literature.

Beta-sitosterol, the predominant plant sterol in most supplements, has robust clinical evidence for improving lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). A Cochrane systematic review of four RCTs confirmed significant improvement in urologic symptom scores and urinary flow measures. Proposed mechanisms include 5-alpha-reductase inhibition and anti-inflammatory effects on prostate tissue.

Pomegranate juice and extract (polyphenols including ellagitannins, punicic acid) have been studied in multiple prostate cancer RCTs. Phase II clinical data showed pomegranate juice significantly prolonged PSA doubling time in patients with rising PSA after primary therapy. However, two subsequent large placebo-controlled RCTs did not confirm significant PSA doubling time lengthening. The Pomi-T trial combining pomegranate with other polyphenols showed significant PSA growth rate reduction.

Prunus africana (pygeum) bark extract has the strongest clinical evidence base of any herbal prostate supplement. A 2002 Cochrane review of 18 RCTs in 1,562 men found moderate improvement in combined urological symptom and flow measures versus placebo. The extract is recognized by the European Medicines Agency and the ESCOP monograph for BPH symptom relief. It does not appear to shrink the prostate gland itself.

Pumpkin seed (Cucurbita pepo) and pumpkin seed oil are approved in Germany for symptomatic BPH treatment. Clinical studies show modest improvements in IPSS and urinary flow. Pumpkin seeds are rich in beta-sitosterol and zinc, both relevant to prostate health. One RCT showed 58% of men on 320 mg pumpkin seed oil daily improved on IPSS vs 39% on placebo after 12 months.

Pygeum (Prunus africana / Pygeum africanum) bark extract has been used in European phytomedicine for BPH for decades. A 2002 Cochrane review of 18 RCTs (1,562 men) concluded it is more effective than placebo for relieving BPH-related lower urinary symptoms including nocturia. It also demonstrates antiproliferative effects on prostate stromal cells in vitro.

Quercetin, a flavonol abundant in onions, apples, and capers, has demonstrated anti-prostate cancer activity in multiple in vitro and in vivo studies, including inhibition of prostate cancer cell growth and enhancement of green tea catechin bioavailability in prostate tissue. A prospective RCT (n=31) confirmed quercetin penetrates prostate tissue. Preclinical studies also show activity against BPH.

A double-blind, placebo-controlled RCT (Noguchi et al., Asian J Andrology, 2008) in 88 men with mild-to-moderate lower urinary tract symptoms found 6 mg/day of reishi extract for 12 weeks significantly improved International Prostate Symptom Score versus placebo. Among 19 mushroom species tested, reishi showed the strongest inhibition of 5-alpha reductase, the enzyme driving benign prostatic hyperplasia. MSKCC confirms clinical improvement of LUTS as an established finding.

Resveratrol, a stilbenoid found in grape skins and Japanese knotweed, has antitumor activity in prostate cancer cells via anti-androgenic, pro-apoptotic, and antioxidant mechanisms. Preclinical and early-phase clinical studies support its role in prostate cancer chemoprevention. An RCT examined high vs. low doses in PSA-recurrent prostate cancer patients. Evidence supports biological activity but not proven clinical efficacy.

Several small human trials and epidemiological studies link whole-grain and bran rye consumption to lower PSA levels and reduced tumor-progression biomarkers in men with prostate cancer. Rye lignans, benzoxazinoids, and reduced insulin signaling are proposed mechanisms. Evidence is promising but derived from small RCTs and requires larger trials.

Saw palmetto (Serenoa repens) is one of the most studied herbal remedies for benign prostatic hyperplasia (BPH). A 2023 review of 27 studies found limited benefit when used alone, though earlier trials and mechanistic studies support 5α-reductase inhibition and anti-inflammatory activity. Native Americans historically used it for urinary and reproductive complaints. Typical studied dose is 320 mg/day of liposterolic extract.

SDG and its metabolite enterolactone suppress benign prostatic hyperplasia (BPH) by inhibiting prostate stromal cell proliferation via the GPER/ERK/p53/p21 pathway. SDG significantly reduced prostatic enlargement and histological abnormalities in BPH animal models. Observational data link higher lignan dietary intake to reduced prostate cancer risk, and clinical evidence suggests 600 mg SDG/day may reduce urinary tract symptoms in BPH.

Selenium has been investigated for prostate cancer prevention based on strong preclinical evidence and an earlier observational study suggesting cancer-protective effects. The large SELECT trial (35,533 men) found neither selenium nor vitamin E reduced prostate cancer incidence after 7 years. Subsequent analysis suggests benefit may be restricted to men with low baseline selenium status. Selenium is included in authoritative prostate supplement reviews.

Epidemiological studies associate high soy/isoflavone intake with lower prostate cancer risk, particularly in Asian populations. Soy isoflavones (genistein, daidzein, equol) inhibit prostate cancer cell proliferation, modulate androgen and estrogen receptor pathways, and reduce PSA in clinical trials. Human RCT evidence is emerging but not yet definitive.

Soy isoflavones (genistein, daidzein, glycitein) have been examined in RCTs for prostate cancer prevention and PSA modulation. Epidemiological data consistently show lower prostate cancer rates in populations with high soy intake. Multiple RCTs have investigated soy isoflavones in men with prostate cancer or elevated risk. A 2020 evidence analysis of RCTs includes soy isoflavones as an examined intervention for PSA modulation.

Epidemiological evidence associates higher soy food consumption with reduced prostate cancer risk in men. A meta-analysis of 30 studies (266,699 participants) demonstrated that total soy consumption is associated with a reduction in prostate cancer risk. However, clinical trial evidence on PSA levels is inconsistent, with most RCTs finding soy or isoflavone supplementation does not significantly affect PSA. Soy isoflavones may modulate androgen receptor activity.

Sulforaphane, derived from glucoraphanin in broccoli and other cruciferous vegetables, inhibits prostate cancer cell proliferation in vitro in a dose-dependent manner and modulates promoter methylation of prostate cancer-related genes. Epidemiological associations between cruciferous vegetable consumption and reduced prostate cancer risk partially attribute to sulforaphane. It acts synergistically with DIM from I3C.

Epidemiological studies consistently associate higher tomato/lycopene intake with reduced prostate cancer risk, and multiple clinical trials have explored lycopene's role in prostate cancer management. A meta-analysis found cooked tomato consumption linked to a modest reduction in prostate cancer risk. Clinical RCTs show lycopene may reduce PSA progression, though evidence remains preliminary and inconsistent.

Lycopene from watermelon accumulates in prostate tissue and has been associated with reduced prostate cancer risk in epidemiological studies. In vitro evidence shows lycopene induces apoptosis and cell cycle arrest in prostate carcinoma cells. Evidence is primarily epidemiological and mechanistic; RCT evidence for prostate cancer prevention is limited.

Zinc is essential for prostate health; the healthy prostate accumulates the highest concentration of zinc of any tissue in the body. Studies show that BPH and prostate cancer tissue have significantly lower zinc levels than normal tissue. Zinc regulates zinc transporters (ZIP1) and supports apoptosis in prostate cells. Evidence for supplementation reducing cancer risk in adequate men is not established.

Buchu has a well-documented traditional and historical herbal use for prostatitis and benign prostatic hyperplasia (BPH). Western herbalists and German herbalists have recommended it for prostate inflammation. Evidence is limited to in vitro mechanistic data and preclinical studies; no clinical trials in prostate conditions exist.

Corn silk has traditional use for prostate conditions including prostatitis and benign prostatic hyperplasia (BPH) in Chinese medicine. A peer-reviewed rodent study showed corn silk extract reduced DHT, PSA, and prostate weight in testosterone-induced BPH. Human clinical evidence is absent.

Corn silk has a documented traditional use for prostatitis and prostate inflammation across herbalism traditions. It is listed for prostate inflammation on authoritative pharmaceutical reference sites such as RxList. No human clinical trials specifically addressing prostate outcomes have been conducted.

Gravel root has been included in traditional Western herbal formulas for prostatitis and urinary symptoms associated with prostate conditions. Its anti-inflammatory and diuretic properties support this traditional use. No clinical trials have assessed it specifically for prostate health.

Hydrangea root has been used in North American folk medicine for centuries for prostate infections and enlarged prostate, attributed to its purported diuretic effects increasing urine flow. RxList and WebMD list enlarged prostate and prostate infections as traditional indications. No human clinical trials have demonstrated efficacy for prostate conditions.

Squawvine is noted in traditional herbal and folk medicine sources as a tonic for the prostate and for use in benign prostatic hyperplasia (BPH). RxList, encyclopedia sources, and Chestnut School of Herbal Medicine document this use. No clinical evidence exists.

Traditional Southeast Asian ethnobotanical records include use of E. longifolia for glandular conditions. Preclinical in-vitro studies have found anticancer properties on human prostate cancer cell lines, described as a potential protectant. No human clinical trials on prostate health outcomes have been conducted. Traditional use and preclinical evidence constitute the current evidence base.